China’s New Biomedical Regulation Changes the Game

China’s biomedical sector is undergoing a profound transformation. Widely referred to within the industry as a “fundamental law,” the Regulation on the Administration of New Biomedical Technology Clinical Research and Translational Clinical Application (hereinafter referred to as the “Regulation”) will be effective on May 1, 2026. The Regulation seeks to install both a “powerful engine” and a “sensitive brake” for a rapidly expanding yet disorder-prone biotechnology sector.

On September 28, 2025, Chinese Premier Li Qiang signed State Council Decree No. 818; on October 10, the Regulation was officially released. From its deliberation and approval at the 68th State Council Executive Meetingon September 12 to formal promulgation, only 28 days elapsed. This unusually fast legislative process reflects both strong policy resolve and the urgency of industrial development.

Just eleven days before the Regulation was announced, encouraging news arrived from the 2025 European Society for Medical Oncology (ESMO) Annual Meeting: China’s innovative drug research achieved a concentrated breakthrough—35 studies were selected for oral presentations, 23 entered the highly prestigious Late-Breaking Abstract (LBA) category, and three were featured at the Presidential Symposium. From PD-(L)1 bispecific antibodies to advances in antibody–drug conjugates (ADCs), Chinese biomedicine is evolving from a “follower” into a “leader.”

However, alongside technological breakthroughs, lagging institutional norms have become a bottleneck constraining the industry’s sustained, high-quality development. The introduction of the new Regulation aims precisely to integrate fragmented practices into a unified national framework, bringing an end to the era of “wild growth.”

This new regulation centers on three major institutional innovations, striving to strike a balance between “encouraging innovation” and “ensuring safety,” thereby reshaping the industry ecosystem.

First -- High Safety Thresholds: Securing the Bottom Line at the Source

The Regulation stipulates that only Grade A tertiary hospitals are eligible to conduct clinical research. Principal investigators must hold physician licenses and senior titles, and all projects must complete non-clinical validation such as laboratory and animal studies. This “front-loaded qualification” mechanism fundamentally eliminates the disorder associated with small-scale, unregulated gene-editing or stem cell research.

More importantly, the Regulation establishes a dynamic evaluation mechanism. All clinical research must be filed with the National Health Commission and is subject to continuous assessment. Once risks are identified, authorities may promptly require suspension or termination of the study. In other words, new technologies are simultaneously equipped with both an “engine” and a “brake.”

Second -- Faster Approval: Clearing the Translational Pathway

This represents the Regulation’s most breakthrough design. Previously, after completing clinical research, a cell or gene therapy product had to reorganize data and undergo re-registration, often resulting in approval cycles lasting several years. Under the new Regulation, research results can directly serve as the basis for application approval, with the entire process capped at a maximum of 20 working days.

This “parallel expressway” will fundamentally change the previous approval marathon, allowing innovative outcome to benefit patients more rapidly. Comparisons of costs for similar stem cell therapies between China and the United States indicate that, as approval efficiency improves, high-quality technologies at “Chinese prices” are likely to reach a broader patient population.

Third -- Strict Penalties: Giving Regulation Real Teeth

The Regulation addresses long-standing concerns that excessive regulation might stifle innovation by adopting a combination of “the strictest penalties and dynamic oversight”. For unauthorized research on prohibited technologies, fines may reach up to 20 times the illegal gains, and responsible individuals may face lifetime bans from professional practice. Fabrication of research data results in direct revocation of medical institution licenses.

At the same time, the Regulation explicitly prohibits charging research participants during the clinical research phase and encourages the purchase of commercial insurance for subjects. Only after technologies mature may fees be charged in accordance with regulations, creating a positive incentive mechanism. This form of “precision regulation” both safeguards patient rights and leaves ample space for compliant innovation.

In short, the Regulation lays down a high-speed highway for compliant innovators while drawing an uncrossable “high-voltage grid” for violators.

Most strategically significant is the Regulation’s expansive definition of “new biomedical technologies.” The scope of application is extended to “disease prevention,” “health promotion,” and “assessment of health status.”

This implies three major shifts. First, immune cell technologies used to enhance immunity in healthy populations are now brought under regulatory oversight. Second, health assessment technologies that previously fell within the domain of medical devices are incorporated into the new technology framework. Third, industry boundaries are expanding comprehensively from “treating disease” to “full life-cycle health management.”

This broadened definition aligns with the global trend of shifting from disease treatment toward prevention and health maintenance, opening up entirely new blue-ocean markets for China’s biomedical industry.

The implementation of the Regulation is widely regarded as a critical milestone in the development of China’s innovative pharmaceutical sector. Once in effect, it is expected to generate a combined impact of “policy dividends + technological dividends.”

On the technological front, China has achieved leapfrog progress in areas such as PDE-PLUS and ADCs, with multiple innovative drugs reaching or exceeding international standards on key indicators. Institutionally, the “filing plus 20-days approval” mechanism improves R&D efficiency, while strict ethical standards promote industry consolidation, enabling truly capable enterprises to stand out. From a market perspective, China’s large patient base, complete industrial chains, relatively low R&D costs, and institutional advantages are likely to attract accelerating inflows of global capital and technology.

As a result, an “end-to-end pathway” from clinical research to translational clinical application has been opened, greatly stimulating innovation enthusiasm among researchers and enterprises. Over the next decade, the trend of the global biomedical innovation center shifting toward China appears increasingly irreversible.

Red Lines and Green Lights: The Art of Institutional Balance

The Regulation both establishes the “red lines” and turn on the“green lights.” The “red lines” are reflected primarily in the strict prohibition of biomedical technologies banned by laws and administrative regulations, as well as research involving major ethical concerns, emphasizing adherence to core principles of research ethics and safety.

Meanwhile, the “green lights” are embodied in priority review mechanisms, the mandated 20-working-day approval timeline, and the establishment of a national management service system for new biomedical technologies. Together, these measures demonstrate the state’s institutional orientation toward encouraging scientific innovation, optimizing administrative processes, and accelerating clinical translation under the premise of safeguarding ethics and safety.

This model of “openness with boundaries and innovation with regulation” epitomizes China’s institutional strengths. It not only responds to core concerns in science and technology ethics but also provides a predictable and sustainable development environment for biomedical innovation.

Global Perspective: The Broader Significance of the China Approach

From a global standpoint, the significance of the Regulation extends beyond domestic legislation. As new biomedical technologies reshape global health governance, the model established by the Regulation—combining “safety baselines, innovation space, dynamic supervision, and rapid translation”—offers a replicable institutional reference for emerging economies.

Its innovation lies in avoiding both the “excessive caution” that suppresses innovation in some countries and the regulatory vacuum that leads to ethical crises in others, presenting a form of “Chinese wisdom” that balances speed, quality, and safety.

Challenges nonetheless remain: how to ensure professional and efficient approvals; how to balance R&D costs with patient accessibility; and how to strengthen the independence of ethics committees. Yet the promulgation of the Regulation marks China’s entry into a new stage of “law-based governance and orderly innovation” in biomedicine. This “fundamental law” of the industry, refined over six years, fills regulatory gaps and lays an institutional foundation for future development.

When the Regulation officially takes effect on May 1, 2026, it will stand as a milestone in China’s pursuit of high-quality biomedical development. For enterprises, it represents both opportunity and challenge in a period of transition; for regulators, a key test of governance capacity; and for the industry as a whole, a historic moment of moving from “wild growth” toward “regulated prosperity.” A new era of a more standardized, efficient, and innovation-driven Chinese biomedical sector has begun.

(Professor Xu Anlong is Dean of the Sun Yat-sen University Institute of Advanced Study Hong Kong, a member of the National Committee of the Chinese People’s Political Consultative Conference. Dr. Liu Yu is a Research Fellow / Young Scientist at the Sun Yat-sen University Institute of Advanced Study Hong Kong, and holds a PhD in History from The Chinese University of Hong Kong.)